HROWHarrow, Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−27% vs 200-day) and a crowded short (+20% of shares).
In a downtrend, below its 50- and 200-day averages. Oversold (RSI 14). Price is −27% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How HROW is trading
Harrow, Inc. is −34% over the past year while the S&P 500 is +18%: 52 points behind the market. Through the fall, its own insiders bought $19K more stock than they sold.
1-year return · S&P 500 +18%
- vs 200-day average
- −27%
vs 200-day average · a clear downtrend
- RSI (14)
- 14
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 46%
Below its 52-week high
Details›
- Last close2026-10-09
- $29.36
- 1 monthS&P 500 +2.7%
- −20%
- 1 yearS&P 500 +18%
- −34%
- 5 yearsS&P 500 +88%
- +214%
- vs 50-day average$36.28
- −19%
- 52-week high
- $54.80
- 52-week low
- $29.03
- Annualised volatility
- 63%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- $19K
| Year | Return |
|---|---|
| 2026 (year to date) | −40% |
| 2025 | +46% |
| 2024 | +200% |
| 2023 | −24% |
| 2022 | +71% |
| 2021 | +26% |
| 2020 | −12% |
| 2019 | +37% |
| 2018 | +235% |
| 2017 | −32% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | −4.1% |
| Feb | 10 | 6 of 10 | +6.2% |
| Mar | 10 | 3 of 10 | −1.5% |
| Apr | 10 | 5 of 10 | +5.5% |
| May | 10 | 6 of 10 | +10% |
| Jun | 10 | 8 of 10 | +8.6% |
| Jul | 11 | 6 of 11 | +1.00% |
| Aug | 11 | 7 of 11 | +8.9% |
| Sep | 11 | 4 of 11 | −0.93% |
| Oct | 11 | 3 of 11 | −2.2% |
| Nov | 10 | 6 of 10 | +3.1% |
| Dec | 10 | 6 of 10 | +9.3% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #22 of 41 by RyuScore